Loading clinical trials...
Loading clinical trials...
Efficacy and Safety Phase IIb Study of Recombinant Human Serum Albumin/ Granulocyte Colony-Stimulating Factor Fusion Protein for Injection to Prevent Neutrophilic Granulocytopenia Among Chemotherapy Breast Cancer Patients
Conditions
Interventions
rHSA-GCSF 2.4mg
GCSF
Locations
1
China
Chinese Academy of Medical Sciences Cancer Hospital
Beijing, Beijing Municipality, China
Start Date
October 19, 2017
Primary Completion Date
July 23, 2018
Completion Date
April 24, 2019
Last Updated
September 13, 2019
NCT06537726
NCT05245487
NCT04101760
NCT02454530
Lead Sponsor
Tianjin SinoBiotech Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions